Skip to content

ILC3 Roles In Pulmonary Disease

Scope

This topic page describes how ILC3s are represented in the current ILC_in_lung wiki as disease-relevant cells in lung and airway contexts. It focuses on bacterial host defense, neonatal lung development, acute lung injury/ARDS, neutrophilic asthma, steroid-resistant asthma, cigarette-smoke-associated asthma, and allergic lung pathology.

This page expands the disease branch of ILC3. Use the entity page for the canonical cell-level model, then use this topic when the question is specifically about disease context and pathology.

Evidence tags

#cell/ILC3 #tissue/lung #tissue/gut #outcome/infection #outcome/homeostasis #outcome/inflammation #outcome/airway_hyperresponsiveness #axis/ILC_lung_homeostasis #axis/ILC_airway_inflammation #axis/ILC_plasticity

Confidence snapshot

  • High confidence: the local source set supports lung ILC3 roles in bacterial IL-22 host defense and neonatal pulmonary niche biology.
  • High confidence: the source set supports an ILC3/IL-17A/neutrophil branch in ARDS, neutrophilic asthma, and steroid-resistant asthma.
  • Medium confidence: cigarette smoke, airway epithelial/fibroblast cues, and glucocorticoid-resistance mechanisms are important disease regulators for ILC3-associated airway inflammation.
  • Medium confidence: ILC3-derived mediators can be protective or pathogenic depending on cytokine output and disease context.
  • Low confidence: extrapolating gut ILC3 regulatory programs into lung disease should remain hypothesis-level unless pulmonary evidence is present.

Established observations

Bacterial infection and mucosal defense

Neonatal lung development and homeostatic niche

ARDS and acute lung injury

Neutrophilic and steroid-resistant asthma

Protease-driven allergic lung pathology

IL-17-producing ILC classification caveat

Extrapulmonary barrier-protection context

  • Gut/mucosal ILC3 sources add several barrier-regulation mechanisms that may be useful comparators for lung interpretation but are not direct pulmonary disease evidence: RANKL/RANK restraint, circadian timing, FFAR2 metabolite sensing, VIP neuroimmune signaling, trained ILC3 defense, and HB-EGF-mediated tissue protection.
  • These mechanisms should be used to generate careful hypotheses about lung ILC3 state control, not as direct support for asthma, ARDS, COPD, or pneumonia claims unless matching pulmonary data are added.

Interpretation

The ILC3 disease model in this wiki is organized around a tension between barrier defense and neutrophil-rich pathology. In bacterial infection and neonatal lung development, ILC3s appear as tissue-supportive cells linked to IL-22, IGF1-responsive developmental niches, and mucosal defense. In ARDS and neutrophilic/steroid-resistant asthma, ILC3s appear as inflammatory amplifiers linked to IL-17A, neutrophil chemoattractants, glucocorticoid resistance, and stromal/fibroblast activation.

The most important interpretation rule is to record which mediator is being discussed:

  • IL-22-dominant ILC3: more often framed around barrier support, epithelial defense, and bacterial host defense.
  • IL-17A/neutrophil-dominant ILC3: more often framed around ARDS, severe asthma, neutrophilic inflammation, mucus, and airway hyperresponsiveness.
  • noncanonical mediator ILC3: includes acetylcholine and possibly other context-specific outputs.
flowchart TD
    accTitle: ILC3 Disease Roles
    accDescr: Working map separating protective and pathogenic pulmonary ILC3 branches.

    ilc3["Pulmonary ILC3"]
    il22["IL-22 branch"]
    il17["IL-17A branch"]
    niche["Stromal niche"]
    ach["Acetylcholine branch"]
    bacteria["Bacterial defense<br/>S. pneumoniae"]
    newborn["Newborn lung<br/>IGF1 niche"]
    ards["ARDS / injury"]
    asthma["Neutrophilic asthma"]
    allergy["Protease allergy"]

    ilc3 --> il22 --> bacteria
    ilc3 --> niche --> newborn
    ilc3 --> il17 --> ards
    il17 --> asthma
    ilc3 --> ach --> allergy

    classDef cell fill:#fff4de,stroke:#b47a1f,stroke-width:2px,color:#4a3108
    classDef branch fill:#e8f3ff,stroke:#3b6ea8,stroke-width:2px,color:#17324d
    classDef disease fill:#eef7ed,stroke:#4d8a50,stroke-width:2px,color:#173d1d

    class ilc3 cell
    class il22,il17,niche,ach branch
    class bacteria,newborn,ards,asthma,allergy disease

Contradiction and supersession

  • Contradiction: ILC3s can be protective in bacterial host defense but pathogenic in IL-17A/neutrophil-rich airway disease.
  • Contradiction: IL-22 and IL-17A are both ILC3-associated outputs, but they map to different disease roles and should not be treated as equivalent.
  • Contradiction: some disease sources may include plastic ILC2/ILC3-like states rather than stable ILC3 populations.
  • Supersession: no current source supersedes the overall ILC3 disease model. The model should be partitioned by mediator, tissue, disease model, and species.

Open questions

  • In the user's project, are ILC3s measured in lung tissue, BAL, sputum, peripheral blood, or scRNA-seq clusters?
  • Are the relevant ILC3s IL-22-dominant, IL-17A-dominant, or mixed?
  • Does the project focus on bacterial infection, viral infection, neutrophilic asthma, steroid-resistant asthma, ARDS, or lung development?
  • Are ILC3-like signals actually stable ILC3s, plastic ILC2s, Th17 cells, gamma-delta T cells, or mixed innate-like lymphocyte populations?
  • Which markers are available to distinguish ILC3s from NK cells, ILC1s, Th17 cells, and ILC2-like plastic states?

Future Expansion Directions

This short appendix highlights future literature directions rather than current disease conclusions. The most useful additions for later versions of this page would be:

  • ILC3 asthma sources that more cleanly separate human association, ex vivo stimulation, and mouse perturbation claims.
  • Additional bacterial-infection and neonatal-lung-niche sources that sharpen the protective branch.
  • More direct source coverage inside ILC3, especially for sputum-versus-lung-tissue compartments, SCF/KIT stromal licensing, and steroid-resistant asthma mechanisms.